跳至主要内容
临床试验/NCT05390970
NCT05390970已完成3 期

Platelet-Rich Plasma Injection for the Treatment of Female Stress Urinary Incontinence: A Randomized Placebo-Controlled Study

Annah J. Vollstedt2 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2022年5月23日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
50
试验地点
2
主要终点
Number of Participants With Negative Urinary Stress Test (no Leakage Noted on Examination During Cough or Valsalva Maneuvers at a Standardized Bladder Volume of 300 mL)

研究概览

简要总结

The aim of this randomized controlled trial study is to evaluate the efficacy and safety of platelet-rich plasma (PRP) in the treatment of female stress urinary incontinence (SUI), compared to placebo. Subjects will undergo an injection of PRP (or injectable saline placebo) into the anterior vaginal wall in the office. Primary outcomes will include a negative urinary stress test plus improvement with the Patient Global Impression of Improvement (PGI-I) at 6-months. Secondary outcomes will include the Female Sexual Function Index (FSFI), the Incontinence Quality of life (I-QOL), Questionnaire for Urinary Incontinence Diagnosis (QUID), and the visual analog scale for pain.

详细描述

Platelet-rich plasma (PRP) is an autologous solution of human plasma with a high concentration of platelets. While the preparation and injection of PRP is not a new technology, it has not been well-studied in the field of urogynecology. Small case series have suggested PRP may be used in the treatment of stress urinary incontinence (SUI). The aim of this randomized controlled trial study is to evaluate the efficacy and safety of PRP in the treatment of female SUI, compared to placebo. Adult females with SUI or with stress-predominant mixed urinary incontinence will be eligible. Subjects will undergo an injection of PRP (or injectable saline) into the anterior vaginal wall in the office. At baseline and at time points of 1, 3, and 6 months, subjects will complete the validated questionnaires. A pelvic exam with a stress test will be performed by a blinded provider at the 3 and 6-month visits. Primary outcomes will include a negative urinary stress test plus improvement with the Patient Global Impression of Improvement (PGI-I) at 6-months. Secondary outcomes will include the Female Sexual Function Index (FSFI), the Incontinence Quality of life (I-QOL), Questionnaire for Urinary Incontinence Diagnosis (QUID), and the visual analog scale for pain.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 99 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Women aged 18 years or older
  • Pure or stress-predominant urinary incontinence with the Medical, Epidemiologic, and Social Aspects of Aging questionnaire (MESA) stress incontinence symptom score greater than MESA urge incontinence symptom score
  • Observation of leakage by provocative stress test at bladder volume £ 300 mL [15]
  • Post void residual < 150 mL

排除标准

  • Currently pregnant or trying to conceive
  • Currently breastfeeding
  • Interstitial cystitis
  • Urgency urinary incontinence predominance or currently being treated for overactive bladder with medication, percutaneous tibial nerve stimulation, bladder chemodenervation, or sacral neuromodulation
  • Currently being treated for a sexually transmitted disease
  • Pelvic organ prolapse greater than stage 2 according to the Pelvic Organ Prolapse Quantification System
  • Periurethral mass
  • Active gynecologic, urologic or colorectal cancer
  • History of pelvic radiation
  • Psychological disorder making the patient unable to provide consent
  • Undiagnosed abnormal uterine bleeding
  • Genitourinary fistula
  • Prior SUI surgery
  • Use of anti-platelet or anti-coagulant medication
  • Regular use of non-steroidal anti-inflammatorie

结局指标

主要结局

Number of Participants With Negative Urinary Stress Test (no Leakage Noted on Examination During Cough or Valsalva Maneuvers at a Standardized Bladder Volume of 300 mL)

时间窗: 6-months

Negative urinary stress test (no leakage noted on examination during cough or Valsalva maneuvers at a standardized bladder volume of 300 mL

Subjective Outcome With Improvement in the Patient Global Impression of Improvement (PGI-I), With Positive Response Defined as "Very Much Better" (1) or "Much Better" (2)

时间窗: 6-months

Answered "very much better" or "much better" on the Patient Global Impression of Improvement (PGI-I)

次要结局

  • Incontinence-Quality of Life (I-QOL) Scores(6-months)
  • Questionnaire for Urinary Incontinence Diagnosis (QUID)(6-months)
  • Visual Analog Scale (VAS) for Patient Pain/Discomfort(after injection)
  • Female Sexual Function Index (FSFI) Scores(6-months)
  • Perception of Monetary Value(6-months)
  • Visual Analog Scale (VAS) for Procedure Difficulty (by Provider)(after injection)

研究者

发起方
Annah J. Vollstedt
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Annah J. Vollstedt

Principle investigator

University of Iowa

研究点 (2)

Loading locations...

相似试验

Platelet-Rich Plasma for Stress Urinary Incontinence | 临床试验